Skills Alliance’s Post

After a challenging three years, hashtag #biotech financing is showing signs of recovery. However, it’s a landscape marked by stark contrasts... 🔍 The Good: Innovation is thriving: Private funding rounds are reaching 15-year highs. M&A activity is robust: Big pharma is still actively acquiring valuable assets. ⚠️ The Challenges: Public markets remain cautious. Early-stage biotechs are struggling to secure necessary funds. 🏆 Winner-Takes-All Environment: Later-stage companies with proven assets and experienced teams are thriving, while others face tough choices like refinancing, merging, or even shutting down. In today’s market, the focus is on quality over quantity. The biotech sector is prioritising experienced talent with a strong track record. For recruitment, this means 💡 Sourcing top professionals in key areas like clinical development, immunology, and AI-driven drug discovery. Connecting high-caliber candidates with the right opportunities to drive the next wave of biotech innovation. As the biotech sector recovers, attracting and retaining the best talent will be more crucial than ever. #Biotech #Innovation #Recruitment #TalentAcquisition #BiotechRecovery #LifeSciences

First, the bad news... If you thought 2023 was a difficult year for biotech and biopharma employment, you aren't wrong. According to research by BioPharma Dive, small and mid-sized drugmakers alone shed more than 10,000 jobs last year. Now, the good news... It's only the first week of January 2024 and we are already seeing signs of new life. If interest rates stabilize and venture capital bounces back, 2024 could be banner year for the biotech and biopharma industries. Here's to a new year! #biotech #biopharma #employment #staffing

If you're thinking about moving from a big pharma company to a smaller early-stage biotech, you gotta check out this blog. I stumbled upon this cool piece by Emily Gransky, and as a fellow biotech recruiter, I totally agree with the points she makes and find some of the information highly valuable. When facing life's decisions, always consider the pros and cons. However, at the end of the day, it's your beliefs that get you out of bed and drive your daily grind. #biotech #newjob #blog

SFBN Feed: The best-paying biotechs in the Bay Area, Boston and San Diego for 2023 https://lnkd.in/gXSa6wNT As part of our analysis of CEO and employee pay in biopharma, Endpoints News analyzed median employee pay in 2023 at 177 life sciences companies. Sixty of the top 100 highest-paying companies were headquartered in the [...] #BayArea #SanFrancisco #Biotech #Lifescience #News

New Dawn for Pharma! 🌅💊 East Coast's pharma and life sciences sector just hit a gold vein of investment! We're seeing an unprecedented inflow of resources - this means state-of-the-art labs, cutting-edge research, and jobs, jobs, jobs! It's not just a win for science, it's a beacon of hope for patients awaiting breakthroughs. The impact? It's monumental. Projected growth rates are skyrocketing. Think more innovation, faster drug development, and a robust industry that sets the global pharma pace. 🚀 As a recruiter in this space I wonder how important Quality Assurance is going to be in ensuring all this investment & growth doesn't fall at the final hurdle due to lack of foresight, buy in and investment across QA! What do you think? #PharmaGrowth #EastCoastInnovation #LifeSciencesBoom

#YearinReview | #7: The sector tackles workforce development challenges As the number of companies and clinical trial programs grows, the sector needs more talent to keep pace. ARM has worked with members to spearhead this issue through our Workforce Gap Analysis Report and Roundtable at #ISCT2023. Additionally, the White House released an action plan this year to rapidly and equitably expand biotechnology and biomanufacturing education and job training programs in the US. https://lnkd.in/gtnAbSZW Read about the workforce gap: https://lnkd.in/g4QTquCF

𝗡𝗮𝘃𝗶𝗴𝗮𝘁𝗶𝗻𝗴 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗧𝗮𝗹𝗲𝗻𝘁 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 𝗶𝗻 𝟮𝟬𝟮𝟰 🚀 As we all know, attracting top-tier talent remains a significant challenge in the Biotech industry. But don't worry, we've developed a comprehensive guide to navigate these obstacles effectively. If you're interested in receiving a copy, comment yes' on this post and I happily share it with you. Stay ahead of the competition and gain valuable insights to enable growth. #biotech #talent #lifesciences

Another illustration of the unique business model of pharma/biotech and its impact on human resources (in one way or another). Research environment is highly volatile & unpredictable - still, many take bold decisions to invest, develop and unfortunately sometimes, fail to bring innovations to market. Hurdles are multiple - and in such context, resilience and humility remain two key factors that will lead to success. The learning journey can be steep, sometimes painful, but always rewarding when it benefits patients' communities. Full support to all those impacted by these changes - and also confidence in what the future can bring, especially in this area.

I've known this for years. A professor explained it to me back in 2017 with a few simple statistics. The waves of redundancies in Pharma are not about to stop. Yes, the pharmaceutical industry is going through a period of 'transformation', i.e. its in-house R&D is no longer (and will be less and less) profitable. And it is tending to outsource and cut the costs of everything it can in order to maximise its profits and continue the race for patents between the giants of the sector through increasingly costly acquisitions. Yes, but also Because large international groups in all sectors automatically recruit less than medium-sized and small companies, which are the real economic fabric of a country. This simple realisation comes to me from a professor at ESSEC Business School. He cross-referenced Insee data with employment data and was thus able to study economic and job creation trends in a country like France between small, medium and large companies. And the conclusion is unassailable: big companies are destroying jobs in developed countries. Keep it in mind when joining a company 😉 #biotech #pharma #lifesciences #healthcare #layoff

India's bioeconomy is estimated to have crossed the $92 billion mark by value in the year 2022 but the talent crunch manifests in various ways. A significant portion of the current workforce lacks specialised skill sets required for high-end research and development activities. Additionally, attracting and retaining top talent often falls victim to stiff competition from established global players, offering lucrative packages and career pathways that India's ecosystem might struggle to match. Experts highlight that attracting and retaining top talent in the biopharma sector is a complex task. The industry faces fierce competition from tech giants and startups luring talent with both high salaries and exciting prospects. Meanwhile, the limited pool of professionals with specialised skill sets like data science and machine learning makes recruitment another thing which companies have to deal with. Natasha Tiwary | AbbVie Shiv Kumar, PCC | Merck India Biopharma Benjamin James | Cytiva #BioPharma #TalentCrunch #Pharma